Search
Dengue virus serotype 4
go.drugbank.com/drugs/DB22667Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalIt is designed to combat colds caused by rhinovirus.
Categories: Amino Acids, Peptides, and ProteinsYKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
EHT899
go.drugbank.com/drugs/DB05108ExperimentalEHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Etretinate
go.drugbank.com/drugs/DB00926ApprovedWithdrawnEtretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.
Thymopentin
go.drugbank.com/drugs/DB11996InvestigationalThymopentin has been used in trials studying the treatment and prevention of HIV Infections and Hepatocellular Carcinoma.
Categories: Antineoplastic and Immunomodulating Agents, Hormones, Hormone Substitutes, and Hormone AntagonistsNorflurane
go.drugbank.com/drugs/DB13116ApprovedInvestigationalWithdrawnNorflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).
Panobacumab
go.drugbank.com/drugs/DB15342InvestigationalPanobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Foralumab
go.drugbank.com/drugs/DB16170InvestigationalForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Categories: Amino Acids, Peptides, and ProteinsAZD7442
go.drugbank.com/drugs/DB15787InvestigationalAZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
Categories: Amino Acids, Peptides, and Proteins